Key result
All-trans retinoic acid significantly inhibited doxorubicin-induced apoptosis in H9c2 cells and primary cardiomyocytes by activating the ERK2 pathway, without compromising anticancer efficacy.
Why the study?
Does All-trans retinoic acid (ATRA) prevent doxorubicin-induced cardiotoxicity in cardiomyocyte models?
Does All-trans retinoic acid (ATRA) prevent doxorubicin-induced cardiotoxicity in cardiomyocyte models?
ATRA demonstrates cardioprotective effects against doxorubicin-induced toxicity in vitro via ERK2 pathway activation without reducing anticancer efficacy.
May protect cardiomyocytes during doxorubicin therapy; leaves open clinical translation of ERK2 activation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2015) studied Doxorubicin-induced cardiotoxicity. All-trans retinoic acid (ATRA) vs. Doxorubicin alone was evaluated on Doxorubicin-induced apoptosis and cardiotoxicity. All-trans retinoic acid significantly inhibited doxorubicin-induced apoptosis in H9c2 cells and primary cardiomyocytes by activating the ERK2 pathway, without compromising anticancer efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: